Find clinical trials for Non-Hodgkin Lymphoma in London, England
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near London, England, GBR:
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
London, United Kingdom and 66 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
London, United Kingdom and 31 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
London, United Kingdom and 73 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
London, United Kingdom and 56 other locations
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...
Phase 1
London, United Kingdom and 14 other locations
study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non...
Phase 2
Sutton, United Kingdom and 16 other locations
(CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non- ...
Phase 1
London, United Kingdom and 5 other locations
additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin...
Phase 1, Phase 2
London, United Kingdom and 19 other locations
targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non- ...
Phase 1
London, United Kingdom and 23 other locations
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 or CC-99282) i...
Phase 1
London, United Kingdom and 26 other locations
Clinical trials
Research sites
Resources
Legal